Cell therapy (CAR-T) · Kills target cells, directed at B-cell maturation antigen (TNFRSF17) · developed by CRISPR Therapeutics
Motacabtagene lurevgedleucel is an allogeneic T-lymphocyte cell therapy gene-edited with CRISPR-Cas9 to disrupt endogenous TCR and MHC class I expression and to express a chimeric antigen receptor targeting BCMA. It binds BCMA-overexpressing cells and kills them through cytotoxic T-lymphocyte activity. It is studied in multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04244656 | Phase 1 | Multiple Myeloma | Terminated | CRSP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Multiple Myeloma
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRSP page.
See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRSP catalysts and pipeline →